ArticleDiabetes, obesity & metabolism2026
Long-acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population-based cohort study.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long-acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin. We compared the risk of diabetic nephropathy associated with the use of long-acting insulin analogues with the use of intermediate-acting NPH insulin among patients with T2D. MATERIALS AND
methodsWe conducted a retrospective cohort study using an active-comparator, new user design and the United Kingdom's Clinical Practice Research Datalink AURUM. Our primary outcome was incident diabetic nephropathy, and our secondary outcomes were chronic kidney disease (CKD) and end-stage renal disease (ESRD). We used Cox proportional hazards models with inverse probability of treatment weighting to estimate hazard ratios (HR) and 95% confidence intervals (CI) for each outcome associated with long-acting insulin analogues versus NPH insulin.
resultsThe incidence rate (per 1000 person-years) of diabetic nephropathy was 16.3 (95% CI: 15.3-17.4) among initiators of long-acting insulin analogues and 17.5 (95% CI: 16.3-18.8) among initiators of NPH insulin. Compared with NPH insulin, long-acting insulin analogues were not associated with the risk of diabetic nephropathy (adjusted HR: 0.94, 95% CI: 0.85-1.04). The adjusted HR was 0.91 (95% CI: 0.88-0.94) for CKD and 0.78 (95% CI: 0.46-1.32) for ESRD.
conclusionsWe did not find an association between use of a long-acting insulin analogue, compared with use of NPH insulin, and the risk of diabetic nephropathy among patients with T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.